Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma?

Abstract

Pancreatic cancer is an aggressive malignancy with increasing incidence. Pancreatic ductal adenocarcinoma (PDAC) accounts for > 90% of pancreatic cancer diagnoses, while other exocrine tumors are much rarer. In this review, we have focused on two rare cancers of the exocrine pancreas: adenosquamous carcinoma of the pancreas (ASCP) and pancreatic acinar cell carcinoma (PACC). The latest findings regarding their cellular and molecular pathology, clinical characteristics, prognosis, and clinical management are discussed. New genetic and transcriptomic data suggest that ASCP is related to or overlaps with the basal transcriptomic subtype of PDAC. These tumors are highly aggressive and driven by activated KRAS and MYC expression. Clinical outcomes remain poor and effective treatments are limited. PACC has no morphologic or genetic resemblance to PDAC and more favorable outcomes. Early stage PACC patients have improved survival with surgical resection and patients with advanced disease benefit most from platinum- or fluoropyrimidine-containing chemotherapy. Frequency of actionable genetic mutations is high in this disease and case reports suggest good outcomes when matched therapy is given. Dedicated clinical studies examining ASCP and PACC are limited and difficult to accrue. Further research is needed to define optimal clinical management for these rare diseases.

Keywords

Adenosquamous carcinoma of the pancreas / acinar cell carcinoma of the pancreas / rare exocrine pancreatic cancer

References

[1] Conroy T,Ychou M.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med2011;364:1817-25

[2] Conroy T,Hebbar M.FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.N Engl J Med2018;379:2395-406

[3] Von Hoff DD,Borad MJ.Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.J Clin Oncol2011;29:4548-54 PMCID:PMC3565012

[4] Neoptolemos JP,Ghaneh P.Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.Lancet2017;389:1011-24

[5] Siegel RL,Fuchs HE.Cancer statistics, 2022.CA Cancer J Clin2022;72:7-33

[6] Rahib L,Aizenberg R,Fleshman JM.Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.Cancer Res2014;74:2913-21

[7] Sung H,Siegel RL.Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[8] Gordon-Dseagu VL,Goggins M.Pancreatic cancer incidence trends: evidence from the surveillance, epidemiology and end results (SEER) population-based data.Int J Epidemiol2018;47:427-39 PMCID:PMC5913617

[9] Falconi M,Kaltsas G.ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.Neuroendocrinology2016;103:153-71 PMCID:PMC4849884

[10] Holly EA,Bracci PM.Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area.Clin Gastroenterol Hepatol2004;2:510-7

[11] Khorana AA.Pancreatic cancer and thromboembolic disease.Lancet Oncol2004;5:655-63

[12] Artinyan A,Prendergast C,Ellenhorn JD.The anatomic location of pancreatic cancer is a prognostic factor for survival.HPB2008;10:371-6 PMCID:PMC2575681

[13] Oettle H,Neuhaus P.Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.JAMA2007;297:267-77

[14] Versteijne E,Suker M.Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized preopanc trial.J Clin Oncol2022;40:1220-30

[15] Versteijne E,Groothuis K.Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III preopanc trial.J Clin Oncol2020;38:1763-73 PMCID:PMC8265386

[16] Von Hoff DD,Arena FP.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med2013;369:1691-703 PMCID:PMC4631139

[17] Burris HA 3rd,Andersen J.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J Clin Oncol1997;15:2403-13

[18] Brahmer JR,Chow LQ.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med2012;366:2455-65

[19] O’Reilly EM,Dhani N.Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial.JAMA Oncol2019;5:1431-8 PMCID:PMC6647002

[20] Hu ZI,Stadler ZK.Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations.Clin Cancer Res2018;24:1326-36 PMCID:PMC5856632

[21] Humphris JL,Nones K.Hypermutation in pancreatic cancer.Gastroenterology2017;152:68-74.e2

[22] Bian J.Pancreatic cancer and immune checkpoint inhibitors-still a long way to go.Transl Gastroenterol Hepatol2021;6:6 PMCID:PMC7724172

[23] Provenzano PP,Chang AE,Von Hoff DD.Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.Cancer Cell2012;21:418-29 PMCID:PMC3371414

[24] Truong LH.Pancreatic cancer microenvironment and cellular composition: current understandings and therapeutic approaches.Cancers2021;13:5028 PMCID:PMC8507722

[25] Jaffee EM,Canto M.Focus on pancreas cancer.Cancer Cell2002;2:25-8

[26] Jones S,Parsons DW.Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.Science2008;321:1801-6 PMCID:PMC2848990

[27] Luo J.KRAS mutation in pancreatic cancer.Semin Oncol2021;48:10-8 PMCID:PMC8380752

[28] Holter S,Dodd A.Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma.J Clin Oncol2015;33:3124-9

[29] Shindo K,Suenaga M.Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma.J Clin Oncol2017;35:3382-90 PMCID:PMC5648172

[30] O’Reilly EM,Zalupski M.Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation.J Clin Oncol2020;38:1378-88 PMCID:PMC7193749

[31] Fogelman D,Oliver G.Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma.Cancer Chemother Pharmacol2015;76:489-98 PMCID:PMC4811030

[32] Reiss KA,Judy R,Nathanson KL.Retrospective survival analysis of patients with advanced pancreatic ductal adenocarcinoma and germline BRCA or PALB2 mutations.JCO Precis Oncol2018;2:1-9

[33] Yu S,Mamtani R.Retrospective survival analysis of patients with resected pancreatic ductal adenocarcinoma and a germline BRCA or PALB2 mutation.JCO Precis Oncol2019;3:1-11

[34] Golan T,Reni M.Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.N Engl J Med2019;381:317-27

[35] Bailey P,Nones K.Genomic analyses identify molecular subtypes of pancreatic cancer.Nature2016;531:47-52

[36] Collisson EA,Olson P.Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.Nat Med2011;17:500-3 PMCID:PMC3755490

[37] Moffitt RA,Flate EL.Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.Nat Genet2015;47:1168-78 PMCID:PMC4912058

[38] Topham JT,Lee MKC.Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics.Clin Cancer Res2021;27:150-7

[39] Hayashi A,Chen R.A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma.Nat Cancer2020;1:59-74 PMCID:PMC8809486

[40] Chan-Seng-Yue M,Wilson GW.Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution.Nat Genet2020;52:231-40

[41] Raghavan S,Navia AW.Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer.Cell2021;184:6119-6137.e26 PMCID:PMC8822455

[42] Porter RL,Thapar V,Szabolcs A,Kulkarni AS,Chougule A.Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma.Proc Natl Acad Sci USA2019;116:26835-45 PMCID:PMC6936349

[43] Madura JA,Doherty MG,Howard TJ.Adenosquamous carcinoma of the pancreas.Arch Surg1999;134:599-603

[44] Board WCoTE. Digestive system tumors. Lyon, France; 2019.

[45] Kardon DE,Przygodzki RM.Adenosquamous carcinoma of the pancreas: a clinicopathologic series of 25 cases.Mod Pathol2001;14:443-51

[46] Murakami Y,Yokoyama Y.Adenosquamous carcinoma of the pancreas: preoperative diagnosis and molecular alterations.J Gastroenterol2003;38:1171-5

[47] Collisson EA,Chang DK.Molecular subtypes of pancreatic cancer.Nat Rev Gastroenterol Hepatol2019;16:207-20

[48] Olson MT,Ali SZ.The differential diagnosis of squamous cells in pancreatic aspirates: from contamination to adenosquamous carcinoma.Acta Cytol2013;57:139-46

[49] Voong KR,Pawlik TM.Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients.Hum Pathol2010;41:113-22 PMCID:PMC3556992

[50] Ito T,Okamura Y.Long-term outcomes after an aggressive resection of adenosquamous carcinoma of the pancreas.Surg Today2019;49:809-19

[51] Lee SM.PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of 56 lesions.Pancreatology2021;21:920-7

[52] Viswanathan K.Pancreatic ductal adenocarcinoma and its variants. In: Pancreas and biliary tract cytohistology. Cham: Springer International Publishing; 2019. pp. 95-145.

[53] Brody JR,Potoczek M.Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma.Mod Pathol2009;22:651-9

[54] Taniwaki S,Sakai H.Sarcomatous component in pancreatic adenosquamous carcinoma: a clinicopathological series of 7 cases.Anticancer Res2019;39:4575-80

[55] Boecker W,Boecker J.Cellular organization and histogenesis of adenosquamous carcinoma of the pancreas: evidence supporting the squamous metaplasia concept.Histochem Cell Biol2020;154:97-105 PMCID:PMC7343762

[56] Lu BC,Yu JH,Yang JH.A huge adenosquamous carcinoma of the pancreas with sarcomatoid change: an unusual case report.World J Gastroenterol2014;20:16381-6 PMCID:PMC4239535

[57] Silvestris N,Pinto R.Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets.Expert Opin Ther Targets2018;22:453-61

[58] Tanigawa M,Akiba J.PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component.Pathol Res Pract2018;214:2069-74

[59] Motojima K,Kohara N,Kanematsu T.Immunohistochemical characteristics of adenosquamous carcinoma of the pancreas.J Surg Oncol1992;49:58-62

[60] Borazanci E,Korn R.Adenosquamous carcinoma of the pancreas: molecular characterization of 23 patients along with a literature review.World J Gastrointest Oncol2015;7:132-40 PMCID:PMC4569590

[61] Fang Y,Xie J.Genomic signatures of pancreatic adenosquamous carcinoma (PASC).J Pathol2017;243:155-9

[62] Lenkiewicz E,Hogenson TL.Genomic and epigenomic landscaping defines new therapeutic targets for adenosquamous carcinoma of the pancreas.Cancer Res2020;80:4324-34 PMCID:PMC7906529

[63] Matsuzaka S,Ono Y.Tracking the clonal evolution of adenosquamous carcinoma, a rare variant of intraductal papillary mucinous neoplasm of the pancreas.Pancreas2016;45:915-8

[64] Liu C,Zhou Y.The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma.Nat Med2014;20:596-8 PMCID:PMC4048332

[65] Witkiewicz AK,Balaji U.Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.Nat Commun2015;6:6744 PMCID:PMC4403382

[66] Polaski JT,Escobar-Hoyos LF.The origins and consequences of UPF1 variants in pancreatic adenosquamous carcinoma.Elife2021;2021:10 PMCID:PMC7846273

[67] Dey P,Zhang J.Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment.Cancer Discov2020;10:608-25 PMCID:PMC7125035

[68] Maddipati R,Baslan T.MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma.Cancer Discov2022;12:542-61 PMCID:PMC8831468

[69] Muthalagu N,Raffo-Iraolagoitia X.Repression of the type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma.Cancer Discov2020;10:872-87 PMCID:PMC7611248

[70] Shukla SK,Abrego J.MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.Oncotarget2015;6:19118-31 PMCID:PMC4662479

[71] Karasinska JM,Kalloger SE.Altered gene expression along the glycolysis-cholesterol synthesis axis is associated with outcome in pancreatic cancer.Clin Cancer Res2020;26:135-46

[72] Somerville TDD,Miyabayashi K.TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma.Cell Rep2018;25:1741-1755.e7 PMCID:PMC6296757

[73] Hamdan FH.DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network.Proc Natl Acad Sci USA2018;115:E12343-52 PMCID:PMC6310858

[74] Andricovich J,Kai Y,Peng W.Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors.Cancer Cell2018;33:512-526.e8 PMCID:PMC5854186

[75] Kalisz M,Beucher A.HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.EMBO J2020;39:e102808 PMCID:PMC7196917

[76] Kloesch B,Paliwal S.A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer.Gut2022;71:766-77 PMCID:PMC9733634

[77] Imaoka H,Mizuno N.Clinical characteristics of adenosquamous carcinoma of the pancreas: a matched case-control study.Pancreas2014;43:287-90

[78] Kaiser J,Mayer P.Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma.Eur J Surg Oncol2021;47:1734-41

[79] Boyd CA,Sheffield KM,Riall TS.415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival.J Surg Res2012;174:12-9 PMCID:PMC3210865

[80] Hester CA,Choti MA.Comparative outcomes of adenosquamous carcinoma of the pancreas: an analysis of the National Cancer Database.J Surg Oncol2018;118:21-30

[81] Katz MH,Al-Refaie WB.Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis.J Gastrointest Surg2011;15:165-74 PMCID:PMC3023036

[82] Yang Z,Zhang P.Development and validation of nomograms to predict overall survival and cancer-specific survival in patients with pancreatic adenosquamous carcinoma.Front Oncol2022;12:831649 PMCID:PMC8940199

[83] Yoshida Y,Ueno M.Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: a multicenter retrospective analysis.Pancreatology2022;22:1159-66

[84] Lozano MD,Sola IJ.FNAC guided by computed tomography in the diagnosis of primary pancreatic adenosquamous carcinoma: a report of three cases.Acta Cytol1998;42:1451-4

[85] Toshima F,Yoshida K.Adenosquamous carcinoma of pancreas: CT and MR imaging features in eight patients, with pathologic correlations and comparison with adenocarcinoma of pancreas.Abdom Radiol2016;41:508-20

[86] Feng YF,Chen HY.110 patients with adenosquamous carcinomas of the pancreas (PASC): imaging differentiation of small (≤ 3 cm) versus large (> 3 cm) tumors.Abdom Radiol2019;44:2466-73

[87] Zhao R,Chen X.CT and MR imaging features of pancreatic adenosquamous carcinoma and their correlation with prognosis.Abdom Radiol2019;44:2822-34

[88] Schawkat K,Jaramillo-Cardoso A.Use of ring-enhancement and focal necrosis to differentiate pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma on CT and MRI.Clin Imaging2021;73:134-8

[89] Ren S,Cui W.Computed tomography-based radiomics signature for the preoperative differentiation of pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma.Front Oncol2020;10:1618 PMCID:PMC7477956

[90] Arco H, Chakiba-Brugère C, Salabert L, Béchade D. Adenosquamous carcinoma of the pancreas.Clin Med Insights Oncol2019;13:1179554919886587 PMCID:PMC6831966

[91] Inomata N,Itani T.An autopsy case of granulocyte colony-stimulating factor-producing pancreatic adenosquamous carcinoma.Clin J Gastroenterol2020;13:448-54

[92] Skafida E,Glava C.Adenosquamous carcinoma of the pancreas: a case report.Cases J2010;3:41

[93] Na YJ,Cho MS.Primary adenosquamous cell carcinoma of the pancreas: a case report with a review of the Korean literature.Korean J Intern Med2011;26:348-51 PMCID:PMC3192208

[94] Kelly K, Moore C. Two rare cases of pancreatic adenosquamous carcinoma: a review of the literature with focus on radiologic findings.Radiol Case Rep2019;14:809-13 PMCID:PMC6554233

[95] Nabae T,Takahata S.Adenosquamous carcinoma of the pancreas: report of two cases.Am J Gastroenterol1998;93:1167-70

[96] Kurdi YM,Roth R.A case of pancreatic adenosquamous carcinoma obstructing the common bile and pancreatic ducts, duodenum, and gastric outlet.Pancreas2016;45:e9-e10

[97] López-Tomassetti-Fernández EM,Delgado-Plasencia L.Hypercalcemia associated with adenosquamous pancreatic carcinoma: a reason to initiate palliative treatment.Rev Esp Enferm Dig2013;105:425-8

[98] Kobayashi N,Iida H.Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM).J Hepatobiliary Pancreat Surg2008;15:531-5

[99] Inoue T,Tajima H.Adenosquamous pancreatic cancer producing parathyroid hormone-related protein.J Gastroenterol2004;39:176-80

[100] Stewart AF.Clinical practice. Hypercalcemia associated with cancer.N Engl J Med2005;352:373-9

[101] Wild AT,Fan KY.Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas.J Gastrointest Oncol2015;6:115-25 PMCID:PMC4311088

[102] Hue JJ,Sugumar K.The importance of multimodal therapy in the management of nonmetastatic adenosquamous carcinoma of the pancreas: analysis of treatment sequence and strategy.Surgery2021;169:1102-9

[103] Altman AM,Marmor S.Completion of adjuvant chemotherapy after upfront surgical resection for pancreatic cancer is uncommon yet associated with improved survival.Ann Surg Oncol2019;26:4108-16

[104] DePeralta DK,Zhou JM.Completion of adjuvant therapy in patients with resected pancreatic cancer.HPB2020;22:241-8 PMCID:PMC7771530

[105] Romano E,Monnier L.Outcomes of vaginal squamous cell carcinoma of patients treated with radiation therapy: a series of 37 patients from a single expert center.Clin Transl Oncol2020;22:1345-54

[106] Maubec E.Update of the management of cutaneous squamous-cell carcinoma.Acta Derm Venereol2020;100:adv00143 PMCID:PMC9189743

[107] Mendenhall WM,Lee AWM.Radiotherapy in the management of glottic squamous cell carcinoma.Head Neck2020;42:3558-67

[108] Lin HN,Shang QX,Yang YS.A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma.Int J Surg2020;80:184-91

[109] Yamaue H,Onishi H.Adenosquamous carcinoma of the pancreas: successful treatment with extended radical surgery, intraoperative radiation therapy, and locoregional chemotherapy.Int J Pancreatol2001;29:53-8

[110] Hsu JT,Chen YR.Adenosquamous carcinoma of the pancreas.Digestion2005;72:104-8

[111] Brunetti O,Marchetti P.Systemic chemotherapy for advanced rare pancreatic histotype tumors: a retrospective multicenter analysis.Pancreas2018;47:759-71

[112] Tanaka N,Matuno T.Response of adenosquamous carcinoma of the pancreas to interferon-alpha, tumor necrosis factor-alpha and 5-fluorouracil combined treatment.Anticancer Res1994;14:2739-42

[113] Noel P,Ng S.Triptolide targets super-enhancer networks in pancreatic cancer cells and cancer-associated fibroblasts.Oncogenesis2020;9:100 PMCID:PMC7653036

[114] Skorupan N,Steinberg SM.A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas.Future Oncol2022;18:2475-81 PMCID:PMC9344435

[115] Klimstra DS,Oertel JE.Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases.Am J Surg Pathol1992;16:815-37

[116] Toll AD,Ali SZ.Acinar cell carcinoma of the pancreas: clinical and cytomorphologic characteristics.Korean J Pathol2013;47:93-9 PMCID:PMC3647135

[117] Klimstra DS,Heffess CS.Mixed acinar-endocrine carcinomas of the pancreas.Am J Surg Pathol1994;18:765-78

[118] Abraham SC,Hruban RH.Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway.Am J Pathol2002;160:953-62 PMCID:PMC1867188

[119] Klimstra DS.Acinar neoplasms of the pancreas-A summary of 25 years of research.Semin Diagn Pathol2016;33:307-18

[120] Thompson ED.Pancreatic neoplasms with acinar differentiation: a review of pathologic and molecular features.Arch Pathol Lab Med2020;144:808-15

[121] La Rosa S,Marchet S.The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia.Virchows Arch2009;454:133-42

[122] Hosoda W,Murakami Y,Shimizu Y.BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens.Pathol Int2013;63:176-82

[123] Said S,Nasr SH.Carboxypeptidase A1 and regenerating islet-derived 1α as new markers for pancreatic acinar cell carcinoma.Hum Pathol2020;103:120-6

[124] Uhlig R,Weidemann S.Carboxypeptidase A1 (CPA1) immunohistochemistry is highly sensitive and specific for acinar cell carcinoma (ACC) of the pancreas.Am J Surg Pathol2022;46:97-104 PMCID:PMC8860221

[125] Jiao Y,Offerhaus GJ.Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.J Pathol2014;232:428-35 PMCID:PMC4048021

[126] Chmielecki J,Frampton GM.Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.Cancer Discov2014;4:1398-405

[127] Jäkel C,Toth R.Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability.Nat Commun2017;8:1323 PMCID:PMC5673892

[128] Furukawa T,Takeuchi S.Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas.Sci Rep2015;5:8829 PMCID:PMC4351513

[129] Chou A,Samra JS,Gill AJ.BRAF gene rearrangements can be identified by FISH studies in pancreatic acinar cell carcinoma.Pathology2018;50:345-8

[130] Prall OWJ,Xu H.RAF1 rearrangements are common in pancreatic acinar cell carcinomas.Mod Pathol2020;33:1811-21

[131] Chou A,Kumarasinghe MP.RET gene rearrangements occur in a subset of pancreatic acinar cell carcinomas.Mod Pathol2020;33:657-64

[132] Gupta M,Krone ME.Targeting the NTRK fusion gene in pancreatic acinar cell carcinoma: a case report and review of the literature.J Natl Compr Canc Netw2021;19:10-5 PMCID:PMC8765083

[133] Liu W,Gönen M,O’Reilly EM.DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance.Pancreas2014;43:1264-70

[134] Kryklyva V,Morsink FHM.Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.Cancer Biol Ther2019;20:949-55 PMCID:PMC6606020

[135] Lee JH,Hariharasudhan G.ID3 regulates the MDC1-mediated DNA damage response in order to maintain genome stability.Nat Commun2017;8:903

[136] Bakr A,Sigismondo G.ID3 promotes homologous recombination via non-transcriptional and transcriptional mechanisms and its loss confers sensitivity to PARP inhibition.Nucleic Acids Res2021;49:11666-89 PMCID:PMC8599806

[137] Xu J,Alewine C.Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci.Cancer Commun2022;42:269-72 PMCID:PMC8923128

[138] La Rosa S,Frattini M.TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer.Virchows Arch2016;468:289-96

[139] Matsuno S,Fukuyama S.Pancreatic cancer registry in japan: 20 years of experience.Pancreas2004;28:219-30

[140] Mustafa S,Ali SZ.Acinar cell carcinoma of the pancreas: a clinicopathologic and cytomorphologic review.J Am Soc Cytopathol2020;9:586-95

[141] Sridharan V,Cleary JM.Pancreatic acinar cell carcinoma: a multi-center series on clinical characteristics and treatment outcomes.Pancreatology2021;1119-26

[142] Schmidt CM,Bentrem DJ,Lillemoe KD.Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma.J Gastrointest Surg2008;12:2078-86

[143] Petrova E,Nording AK.Survival outcome and prognostic factors for pancreatic acinar cell carcinoma: retrospective analysis from the german cancer registry group.Cancers2021;13:6121 PMCID:PMC8656891

[144] Duorui N,Zhang T.The contemporary trend in worsening prognosis of pancreatic acinar cell carcinoma: a population-based study.PLoS One2020;15:e0243164 PMCID:PMC7746196

[145] Wisnoski NC,Nealon WH,Riall TS.672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma.Surgery2008;144:141-8

[146] Seo S,Kim KP.Clinical outcomes of patients with resectable pancreatic acinar cell carcinoma.J Dig Dis2017;18:480-6

[147] Shin SH,Jang JY.Clinical characteristics of resected acinar cell carcinoma of the pancreas: a korean multi-institutional study.Cancers2021;13:5095 PMCID:PMC8534044

[148] Huang X,Zhang L,Lu H.Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: a single institutional comparison to pancreatic ductal adenocarcinoma.Surg Oncol2021;37:101528

[149] Seket B,Scoazec JY.[Pancreatic acinar cell carcinoma in a patient with familial adenomatous polyposis].Gastroenterol Clin Biol2003;27:818-20

[150] Karamurzin Y,Stadler ZK.Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature.Hum Pathol2012;43:1677-87

[151] Li M,Hou S,Li A.Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: a case report.Medicine2018;97:e13113 PMCID:PMC6250555

[152] Labate AM,Zakowski MF.Comparative cytologic features of pancreatic acinar cell carcinoma and islet cell tumor.Diagn Cytopathol1997;16:112-6

[153] Stelow EB,Shami VM.Cytology of pancreatic acinar cell carcinoma.Diagn Cytopathol2006;34:367-72

[154] Tharian B,Krall K,Hébert-Magee S.Ring around the ROSE: pancreatic acinar cell carcinoma diagnosed on site by EUS-FNA.Gastrointest Endosc2015;81:1049-50

[155] Toyonaga Y,Yamada M,Koyama Y.Brush cytology of acinar cell carcinoma of the pancreas with intraductal growth: a case report.Diagn Cytopathol2014;42:321-4

[156] Peng HQ,Papadimitriou JC.Liver metastases of pancreatic acinar cell carcinoma with marked nuclear atypia and pleomorphism diagnosed by EUS FNA cytology: a case report with emphasis on FNA cytological findings.Cytojournal2006;3:29 PMCID:PMC1779360

[157] Barat M,Gaujoux S.Computed tomography features of acinar cell carcinoma of the pancreas.Diagn Interv Imaging2020;101:565-75

[158] Jornet D,Terris B.MR imaging features of pancreatic acinar cell carcinoma.Diagn Interv Imaging2019;100:427-35

[159] Matos JM,Turrini O.Pancreatic acinar cell carcinoma: a multi-institutional study.J Gastrointest Surg2009;13:1495-502

[160] Singh S,Konia T.Pancreatic acinar cell carcinoma-induced panniculitis.JAAD Case Rep2018;4:719-21 PMCID:PMC6098203

[161] Nizam W,Rajack F,Naab T.Lipase hypersecretion syndrome: a rare cutaneous manifestation of advanced pancreatic acinar cell carcinoma.Clin Case Rep2020;8:905-10 PMCID:PMC7250977

[162] Good AE,Kawanishi H,Rapp R.Acinar pancreatic tumor with metastatic fat necrosis: report of a case and review of rheumatic manifestations.Am J Dig Dis1976;21:978-87

[163] Burns WA,Hamosh M,Blum R.Lipase-secreting acinar cell carcinoma of the pancreas with polyarthropathy.A light and electron microscopic, histochemical, and biochemical study.Cancer1974;33:1002-9

[164] Taskin OC.Lipase hypersecretion syndrome: a distinct form of paraneoplastic syndrome specific to pancreatic acinar carcinomas.Semin Diagn Pathol2019;36:240-5

[165] Askan G,Klimstra DS.Expression of markers of hepatocellular differentiation in pancreatic acinar cell neoplasms:  a potential diagnostic pitfall.Am J Clin Pathol2016;146:163-9 PMCID:PMC5731433

[166] Patel DJ,Sweigert P.Clinically resectable acinar cell carcinoma of the pancreas: is there a benefit to adjuvant systemic therapy?.Am J Surg2020;219:522-6

[167] Landa K,Nussbaum DP,Blazer DG 3rd.Underutilization of surgical resection in patients with pancreatic acinar cell carcinoma.HPB2019;21:687-94

[168] Burchard PR,Melucci A.Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma.J Surg Oncol2022;125:856-64 PMCID:PMC9082653

[169] Yoo C,Kim KP.Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: potentially improved efficacy with oxaliplatin-containing regimen.Cancer Res Treat2017;49:759-65 PMCID:PMC5512358

[170] Hiyoshi M,Hamada T,Imamura N.Curative remnant total pancreatectomy for recurrent pancreatic acinar cell carcinoma: a case report.Int J Surg Case Rep2022;94:107091 PMCID:PMC9046634

[171] Ohara Y,Enomoto T.Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report.World J Surg Oncol2018;16:158 PMCID:PMC6091145

[172] Di Marco M,De Lorenzo S.Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: a case report.World J Clin Cases2020;8:1241-50 PMCID:PMC7176612

[173] Sumiyoshi T,Okabayashi T.Long-term survival following pancreatectomy and s-1 chemotherapy for pancreatic acinar cell carcinoma with peritoneal dissemination: a case report and literature review.Medicine2015;94:e378 PMCID:PMC4602841

[174] Cananzi FC,Lorenzi B.“Chronic” metastatic pancreatic acinar cell carcinoma.Pancreatology2013;13:549-52

[175] Jauch SF,Jensen CT.Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: a case report.Pancreatology2016;16:153-6

[176] Jimbo M,Baliff JP.Neoadjuvant chemotherapy and appleby procedure for pancreatic acinar cell carcinoma: a case report.Case Rep Pancreat Cancer2016;2:46-9 PMCID:PMC6319679

[177] Takahashi H,Shiba S.Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens.Pancreas2021;50:77-82 PMCID:PMC7748047

[178] Xu JY,Lu SX.Optimizing chemotherapy of pancreatic acinar cell carcinoma: our experiences and pooled analysis of literature.Clin Med Insights Oncol2022;16:11795549221090186 PMCID:PMC9058357

[179] Lowery MA,Shia J.Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy.Oncologist2011;16:1714-20 PMCID:PMC3248770

[180] Schempf U,König C,Bitzer M.FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report.Z Gastroenterol2014;52:200-3

[181] Hashimoto M,Suzuki T.Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma.Clin J Gastroenterol2017;10:564-9

[182] Busch E,Agaimy A.Successful BRAF/MEK inhibition in a patient with BRAF(V600E)-mutated extrapancreatic acinar cell carcinoma.Cold Spring Harb Mol Case Stud2020;6:a005553 PMCID:PMC7476408

[183] Cramer S,Ramkissoon S,Pressey JG.Pediatric BRAF (V600E)-mutated pancreatic acinar cell carcinoma with complete and durable response to dabrafenib and trametinib.JCO Precis Oncol2020;4:801-5

[184] Gaule M,Quinzii A.Exceptional clinical response to alectinib in pancreatic acinar cell carcinoma with a novel ALK-KANK4 gene fusion.JCO Precis Oncol2022;6:e2100400 PMCID:PMC8769132

[185] Maehira H,Mori H.Pathological complete response in a patient with metastatic pancreatic acinar cell carcinoma who received a chemotherapy regimen containing cisplatin and irinotecan.Clin J Gastroenterol2021;14:1772-8

[186] Qin L,Yang Y.Rapid response to the combination of lenvatinib and sintilimab in a pancreatic acinar cell carcinoma patient with elevated alpha-fetoprotein: a case report.Front Oncol2021;11:692480 PMCID:PMC8564141

[187] Finn RS,Ikeda M.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[188] Makker V,Vogelzang NJ.Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol2019;20:711-8

[189] Tiriac H,Engle DD.Organoid profiling identifies common responders to chemotherapy in pancreatic cancer.Cancer Discov2018;8:1112-29 PMCID:PMC6125219

[190] O’Kane GM,Jang GH.GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer.Clin Cancer Res2020;26:4901-10